Applications are invited from Indian Citizens for recruitment to the following permanent posts:
Post: Senior Pharmacist
Daiichi Sankyo Company, Limited's generics subsidiary, Daiichi Sankyo Espha, will launch seven new generic drugs with four new active ingredients. The products: Naftopidil OD tablets 25mg, 50mg, 75mg “DSEP” (Flivas OD tablets 25mg, 50mg, 75mg) for the treatment for urination disorder due to enlargement of prostate; Metformin hydrochloride tablets 250mgMT, 500mgMT “DSEP” (Metgluco tablets 250mg, 500mg) for biguanide-type oral hypoglycemic agent; Letrozole tablets 2.5mg “DSEP” (Femara tablets 2.5mg) Aromatase inhibitor/postmenopausal breast cancer treatment; Oxaliplatin IV infusion solution 200mg “DSEP” (Elplat IV infusion solution 200mg) anti-malignant tumour agent.
Cinnamaldehyde, chemical constituent of cinnamon has distinctive flavor and smell. Associate Professor Georg Wondrak, and Professor Donna Zhang, at the University of Arizona recently completed a study in which they proved that adding cinnamaldehyde, the compound that gives cinnamon its distinctive flavor and smell, to the diet of mice protected the mice against colorectal cancer. In response to cinnamaldehyde, the mice's cells had acquired the ability to protect themselves against exposure to a carcinogen through detoxification and repair.
Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa®) in patients requiring urgent anticoagulant reversal. No safety concerns relating to idarucizumab* were identified. The results have been simultaneously published in the New England Journal of Medicine (NEJM) and presented today at the International Society of Thrombosis and Haemostasis 2015 Congress in Toronto, Canada.
Dr. Reddy’s today announced the launch of HAiROOTZ™, the first hair growth supplement to be marketed in India as over-the-counter (OTC) by the company. HAiROOTZ™ comes from the same branch of business that markets MINTOPTM, the No. 1 dermatologist recommended brand in the country.
Researchers have successfully engineered E coli bacteria to produce new forms of antibiotics — including three that show promise in fighting drug-resistant bacteria. Blaine A Pfeifer, an associate professor of chemical and biological engineering in the University at Buffalo School of Engineering and Applied Sciences, has been studying how to engineer Escherichia coli (E coli) to generate new varieties of erythromycin, a popular antibiotic.